2.2200
08-يناير-25 15:45:00
15 متأخرة بدقائق
الأسهم
-0.0400
-1.77%
نطاق اليوم
2.1600 - 2.3392
ISIN
N/A
المصدر
NASDAQ
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
18 أبريل 2024 06:00:00 بحسب Nasdaq GlobeNewswire
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
02 أبريل 2024 06:00:00 بحسب Nasdaq GlobeNewswire
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
25 مارس 2024 06:06:46 بحسب Nasdaq GlobeNewswire